Phaseline

Companies › iRegene Therapeutics

iRegene Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 1; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NouvNeu001–Phase 1Early-onset Parkinson's Disease; Parkinson Disease; Multiple System Atrophy - Parkinsonian Subtype (MSA-P)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06608355NouvNeu001Phase 1Early-onset Parkinson's DiseaseNeurologyMar 2027
NCT07102342NouvNeu001Phase 1Parkinson DiseaseNeurologySep 2027
NCT07289477NouvNeu001Phase 1Multiple System Atrophy - Parkinsonian Subtype (MSA-P)NeurologyOct 2027
NCT06167681NouvNeu001Phase 1Parkinson DiseaseNeurologyJul 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.